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Reﬁned human artiﬁcial chromosome vectors for
gene therapy and animal transgenesis
Y Kazuki1,2, H Hoshiya1, M Takiguchi1, S Abe1, Y Iida1, M Osaki1, M Katoh3, M Hiratsuka4, Y Shirayoshi5,
K Hiramatsu1, E Ueno1, N Kajitani1, T Yoshino6, K Kazuki1, C Ishihara1, S Takehara1, S Tsuji1, F Ejima7,10,
A Toyoda7,10, Y Sakaki7,11, V Larionov8, N Kouprina8 and M Oshimura1,2,9
Human artiﬁcial chromosomes (HACs) have several advantages as gene therapy vectors, including stable episomal maintenance,
and the ability to carry large gene inserts. We previously developed HAC vectors from the normal human chromosomes using a
chromosome engineering technique. However, endogenous genes were remained in these HACs, limiting their therapeutic
applications. In this study, we reﬁned a HAC vector without endogenous genes from human chromosome 21 in homologous
recombination-proﬁcient chicken DT40 cells. The HAC was physically characterized using a transformation-associated
recombination (TAR) cloning strategy followed by sequencing of TAR-bacterial artiﬁcial chromosome clones. No endogenous
genes were remained in the HAC. We demonstrated that any desired gene can be cloned into the HAC using the Cre-loxP system
in Chinese hamster ovary cells, or a homologous recombination system in DT40 cells. The HAC can be efﬁciently transferred
to other type of cells including mouse ES cells via microcell-mediated chromosome transfer. The transferred HAC was stably
maintained in vitro and in vivo. Furthermore, tumor cells containing a HAC carrying the suicide gene, herpes simplex virus
thymidine kinase (HSV-TK), were selectively killed by ganciclovir in vitro and in vivo. Thus, this novel HAC vector may be useful
not only for gene and cell therapy, but also for animal transgenesis.
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INTRODUCTION
Conventional gene transfer techniques using viruses, plasmids, P1
phage-derived artiﬁcial chromosomes (PACs), bacterial artiﬁcial chro-
mosomes (BACs) and yeast artiﬁcial chromosomes (YACs), can insert
DNA randomly into the host genome,1 possibly causing cancer in
humans and unpredicted expression in transgenic animals.2–5 Human
artiﬁcial chromosomes (HACs) exhibit several important character-
istics desired for an ideal gene delivery vector, including stable
episomal maintenance, and the capacity to carry large genomic loci
with their regulatory elements, thus allowing physiological regulation
of the introduced gene in a manner similar to that of the native
chromosome.6 HACs have been generated using either a ‘top–down
approach’ (engineered chromosome), or a ‘bottom–up’ approach
(de novo artiﬁcial chromosome).7 Although several groups have
reported functional analyses in vitro using de novo HACs, several
factors limit the application of de novo generated HACs as gene
delivery vehicles. The most critical problem is their undeﬁned struc-
ture and the unpredictable relationship between the input DNA and
resultant HAC, especially in terms of their size and composition.8–10
On the other hand, several groups have reported the creation of
engineered HACs by random segmentation or targeted telomere-
associated chromosomal fragmentation in homologous recombina-
tion-proﬁcient chicken DT40 cells.11–14 We previously developed
HAC vectors from normal human chromosome 14 (hChr.14) or 21
(hChr.21) by the engineering approach, and named the products
SC20-HAC and 21DqHAC/21DpqHAC.13,14 The SC20-HAC was
transmittable through the germline and was rather stable in mice
and cattle.13,15–17 Both 21DqHAC and 21DpqHAC were very stable in
human cell lines.14,18,19 However, SC20-HAC and 21DqHAC/
21DpqHAC contain several structurally undeﬁned regions carrying
many endogenous genes, which cause partial trisomy in cells propa-
gating these HACs. This may affect physiological gene expression and
normal development. Although these HACs showed signiﬁcant poten-
tial for gene therapy and animal transgenesis, the ideal gene delivery
vector should be structurally deﬁne da n ds h o u l dn o tc o n t a i ne n d o g e n -
ous genes from the original chromosome. In this study, we developed a
novel HAC vector of known sequence containing no endogenous genes
using the top–down approach. We also developed several gene insertion
systems on the HAC for functional analysis of multiple genes, safe
human gene therapy and efﬁcient animal transgenesis.
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Construction of 21HAC1
Previously, we developed a HAC vector from normal hChr.21 by a
top–down approach using sequence information from hChr.21.14,20
However, several transcripts were identiﬁed on the previously devel-
oped 21DqHAC/21DpqHAC.21 Thus, we have attempted to construct
a HAC containing no endogenous genes from hChr.21 (Figure 1).
Truncation of hChr.21 and insertion of loxP into hChr.21 was carried
out based on a new information on the structure of pericentromeric
regions of the hChr.21.21 We developed new vectors with targeting
sequences from contigs (AP001657 and AL163201) that are the most
proximal to the centromeric alphoid DNA array. Although the
pericentromeric sequences of AP001657 and AL163201 are not repe-
titive and mostly unique, the nature of these pericentromeric
sequences has not been reported. As we cannot conﬁrm where
the targeting construct was inserted if the repetitive alpha satellite
sequence is used for the targeting, we utilized the known and unique
sequence for the construction of the targeting vector. Such a strategy
allowed us to construct a HAC lacking any endogenous genes. The
21DqHAC/21DpqHAC contained a 3¢neo-loxP site for cloning a
desired gene by reconstitution of the neo cassette. In this study,
5¢HPRT-loxP was used to clone a desired gene by reconstitution of
the HPRT cassette, because the neo gene frequently has been used for
gene-targeting and chromosome-tagging in A9 cell libraries containing
a single human chromosome.22,23 As DT40 cells exhibit a high
frequency of homologous recombination between exogenous DNA
templates and their chromosomal counterparts, DT40 cells containing
hChr.21 tagged with pSTneo were used for modiﬁcation of hChr.21. A
schematic diagram of the construction of the HAC and its map are
shown in Figures 1a and f, respectively. With the targeting construct,
5¢HPRT-loxP-Hyg-TK, for the cloning site (loxP) and negative selec-
tion (herpes simplex virus thymidine kinase (HSV-TK)), 46 of 237
drug-resistant clones selected in the presence of both hygromycin and
G418 were targeted correctly, as shown by PCR and Southern blot
analyses (designated as hChr.21-loxP) (Supplementary Figures S1a
and b). Fluorescence in situ hybridization (FISH) analyses showed that
the targeting construct was integrated into the hChr.21 in DT40 cells
(Figures 1b and c). With the targeting construct, pBS-TEL/Dp Puro,
for the deletion of the p-arm of hChr.21, 3 of 206 drug-resistant clones
selected in the presence of both puromycin and hygromycin were
targeted correctly, as shown by PCR (designated as hChr.21-loxPDp)
(Supplementary Figure S1c). FISH analyses showed that the targeting
construct was integrated into the hChr.21-loxP in DT40 cells
(Figure 1d). With the targeting construct, pBS-TEL/Dq HisD, for
the deletion of the q-arm of hChr.21, 2 of 95 drug-resistant clones
selected in the presence of L-histidinol, puromycin and hygromycin
were targeted correctly, as shown by PCR (designated as hChr.21-
loxPDpq or 21HAC1) (Supplementary Figure S1d). FISH analyses
showed that the targeting construct was integrated into the hChr.21-
loxPDp in DT40 cells (Figure 1e). These data show that a HAC vector
devoid of endogenous genes has been developed. Next, we tested
whether desired gene(s) could be cloned into the HAC using several
methods (Figure 2). Detailed genetic maps of the 21HAC1, 21HAC2,
21HAC3 and 21HAC4 in the following analyses, were shown in
Figure 3.
Gene cloning into 21HAC1 by homologous recombination
To simplify further analysis of mitotic stability of the HAC, the
ﬂuorescent markers, enhanced green ﬂuorescent protein (EGFP)a n d
DsRed, were introduced into the 21HAC1 using homologous recom-
bination in chicken DT40 cells. Homologous recombination in DT40
cells has been used for the modiﬁcation of hChr.21 as described above,
and the Cre-loxP system has been used for gene insertion into the
21DqHAC/21DpqHAC.14 In this study, we used homologous recom-
bination for sequential gene cloning into the 21HAC1 in DT40 cells, as
Figure 1 Construction of 21HAC1 from hChr.21. (a) Strategy for construction of 21HAC1 from hChr.21. (b–e) FISH analyses for DT40 (hChr.21) (b),
DT40 (hChr.21-loxP) (c), DT40 (hChr.21-loxPDp) (d) and DT40 (hChr.21-loxPDpq/21HAC1) (e). Digoxigenin-labeled human COT-1 DNA (red) was used to
detect the HAC. Biotin-labeled PGK-Hyg, PGK-Puro and b-actin-HisD (green) were used to detect the marker gene on the HAC in c, d and e, respectively.
Chromosomal DNA was counterstained with 4,6-diamidino-2-phenylindole (DAPI). The insets show an enlarged image of the modiﬁed hChr.21 (HAC) (arrow).
(f) Map of the 21HAC1 vector.
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Gene Therapywell as for its modiﬁcation (Figure 2a). First, to insert the EGFP gene
into the 21HAC1 as a model, a targeting construct (designated as
I-EGFP-I-Bsd) with homologous arms, the EGFP ﬂanked by HS4
insulator and blasticidin genes, was inserted in the proximal region
of the targeting site of 5¢HPRT-loxP-Hyg-TK (Supplementary Figure
S2a). Since we previously succeeded tissue-speciﬁc gene expression on
the 21DpqHAC using chicken-derived HS4 insulator to block the
promoter interference, we also utilized the HS4 for gene expression on
Figure 2 Schematic diagram of cloning genes into the 21HAC vector. (a) Homologous recombination-type cloning (sequential gene insertion). The desired
gene can be sequentially cloned into a speciﬁc site on the HAC in DT40 cells by homologous recombination. The 21HAC2 can be transferred to the hiMSC,
mES and HT1080 for each experiment via CHO (hprt / )(21HAC2) cells. (b) Insertion-type cloning-1 (HPRT version). The 21HAC1 can be transferred to
CHO (hprt / ) cells. A circular vector can be cloned into the HAC in CHO (hprt / ) cells by Cre-loxP-mediated gene insertion with reconstitution of
the HPRT gene. (c) Insertion-type cloning-2 (neo version). The 21HAC4 modiﬁed from 21HAC1 can be transferred to CHO-K1 cells. A circular vector can be
cloned into the HAC in CHO-K1 cells by Cre-loxP-mediated gene insertion with reconstitution of the neo gene.
Figure 3 Detailed map of 21HACs. (a–f) shows homologous regions on hChr.21 for the targeting. The targeting vector, I-EGFP-I-Bsd, DsRed-neo and 3¢neo-
loxP-Bsd-TK were inserted into the 21HAC1, 21HAC2 and 21HAC1, respectively. The information of the targeting vectors was described in Supplementary
Figure S1–S4. The hook for the TAR cloning vector is described in the loci of the 21HAC4.
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Gene Therapythe 21HAC1.18 With the targeting construct, I-EGFP-I-Bsd, 11 of 47
drug-resistant clones selected in the presence of both blasticidin S and
hygromycin were targeted correctly, as proven by PCR (this HAC was
designated as 21HAC2). FISH analyses showed that the targeting
construct was integrated into the 21HAC1 in DT40 cells (Figure 4a).
Most of the cells were positive for EGFP, showing that the HAC was
retained stably and the EGFP gene on the HAC was expressed stably in
DT40 cells (Figure 4g). Second, to insert the DsRed gene into the
21HAC2 as a model, the targeting constructs (designated as DsRed-
neo) with the homologous arms, DsRed gene and neomycin (neo)
gene, were inserted in the proximal region of the targeting site of the
I-EGFP-I-Bsd (Supplementary Figure S2b). With the targeting con-
struct, DsRed-neo, 34 of 79 drug-resistant clones selected in the
presence of both blasticidin S and G418 were targeted correctly, as
shown by PCR (designated as 21HAC3). FISH analyses showed that
the targeting construct was integrated into the 21HAC2 in DT40 cells
(Figure 4b). Most of the cells were positive for DsRed, showing that
the HAC was retained stably and the DsRed gene on the HAC
expressed stably in DT40 cells (Figure 4g). These data suggest that
multiple genes can be inserted into the HAC using the homologous
recombination approach, and that the expression of these genes was
stable. Next, we tested gene cloning into the HAC by Cre-loxP system
(Figures 2b and c).
Gene cloning into 21HAC1 by Cre-loxP system (HPRT version)
In this study, Cre-loxP-mediated gene insertion into the 21HAC1 in
DT40 cells using HPRT gene reconstitution could not be used, because
we used hprt-positive DT40 cell lines. Therefore, the 21HAC1 was
transferred to hprt-deﬁcient Chinese hamster ovary (CHO) (hprt / )
cells via microcell-mediated chromosome transfer (MMCT). PCR
analyses with 21HAC1-speciﬁc primers showed that 22 out of the
38 drug-resistant clones were positive for 21HAC1 (data not shown).
FISH analysis showed that the 21HAC1 was successfully transferred
into the CHO (hprt / ) cells (Figure 4c). To test whether a circular
vector with a desired gene can be cloned into the 21HAC1 in CHO
(hprt / ), a Cre-expression vector and a plasmid vector containing
the EGFP ﬂanked by HS4 insulator, loxP and 3¢HPRT (I-EGFP-I-loxP-
3¢HPRT), were co-transfected into CHO (hprt / ) cells containing
the 21HAC1, and recombinant clones were selected using hypox-
anthine - aminopterin - thymidine (HAT) over a period of 10 days
(Supplementary Figure S3). In all, 4 out of 12 drug-resistant clones
were positive by PCR with GFP-speciﬁc primers and were positive for
GFP (Figure 4h), suggesting that the remaining 8 clones have some
rearrangements or deletions for the GFP expression. FISH analyses
showed that the construct was inserted into the 21HAC1 in CHO
(hprt / ) cells (Figure 4d). This ratio (4 of 12, or 33%) of circular
vector insertion into the 5¢HPRT-loxP site on the 21HAC1 by HPRT
Figure 4 Analysis of a HAC containing desired genes. (a–f) FISH analyses for DT40 (21HAC2) (a), DT40 (21HAC3) (b), CHO (21HAC1) (c), CHO (GFP-
21HAC1) (d), CHO (21HAC4) (e) and CHO (HPRT-21HAC4) (f). Digoxigenin-labeled human COT-1 DNA (red) was used to detect the HAC. Biotin-labeled
CAG–EGFP, CMV-DsRed and RP6-127C8 (green) were used to detect the marker gene on the HAC in (a and d), (b)a n d( f), respectively. Chromosomal DNA
was counterstained with 4,6-diamidino-2-phenylindole (DAPI). The inset shows an enlarged image of the HAC (arrow). (g) Expression of the ﬂuorescent gene
on the HAC in DT40 cells. Phase-contrast (top panel), GFP-ﬂuorescence (middle panel) and DsRed-ﬂuorescence (bottom panel) micrographs are shown.
(h) Expression of the ﬂuorescent gene on the 21HAC1 in CHO cells. (i) Representative genomic PCR and reverse transcriptase (RT)-PCR data for detecting
HPRT-21HAC4 in CHO cells. HT1080 and CHO (21HAC4) cells were used as positive and negative controls, respectively. b-actin was used as an internal
control.
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Gene Therapygene reconstitution was comparable to that into the 3¢neo-loxP site on
the 21DqHAC/21DpqHAC by neo gene reconstitution.14 These data
suggest that a desired gene can be cloned into the 21HAC1 by the
Cre-loxP system without utilizing a neo gene.
Gene cloning into 21HAC4 by Cre-loxP system (neo version)
In the Cre-loxP system previously developed on the 21DqHAC/
21DpqHAC, desired genes were cloned using the neo gene reconstitu-
tion. Furthermore, one of the human BAC/PAC libraries constructed
for the human genome sequencing project,24 RPCI-6, has a 5¢neo-loxP
site, thus allowing the BAC/PAC inserts to transfer readily into the
21DqHAC/21DpqHAC vector with 3¢neo-loxP-Bsd. To load previously
developed vectors or the RPCI-6 library into the novel 21HAC1 vector
developed in this study, the 3¢neo-loxP-Bsd cassette was inserted into
the 21HAC1 in DT40 cells instead of the 5¢HPRT-loxP-Hyg cassette.
With the targeting construct, 3¢neo-loxP-Bsd-TK for the cloning site
(loxP) and negative selection (HSV-TK), 18 of 58 drug-resistant clones
selected in the presence of blasticidin S were targeted correctly, as
shown by PCR (designated as 21HAC4) (Supplementary Figure S4a).
FISH analyses showed that the targeting construct was integrated into
the correct locus on the 21HAC1 in DT40 cells (data not shown).
Then, the 21HAC4 was transferred to CHO-K1 cells from DT40 cells
via MMCT (Figure 4e). To test whether a desired gene can be cloned
into the 21HAC4 by neo gene reconstitution, a PAC containing the
HPRT gene and a 5¢neo-loxP site, RP6-127C8, which was previously
screened,19 as well as a Cre-expression vector were co-transfected into
CHO-K1 cells containing 21HAC4, and the recombinant clones were
selected using G418 over a period of 7 days (Figure 2c and Supple-
mentary Figure S4b). In all, 2 out of 10 drug-resistant clones were
positive by PCR with HPRT-speciﬁc primers and by FISH analysis,
and expressed the human HPRT gene by reverse transcriptase-PCR
analysis (Figures 4f and i). This ratio (2 of 10, or 20%) of the PAC
vector insertion into the 3¢neo-loxP site on the 21HAC4 by neo gene
reconstitution was comparable to the previous study.19 These data
show that the previously developed plasmid vector for cloning into the
21DqHAC/21DpqHAC or the screened RPCI-6 vector can be used for
cloning into the 21HAC4 using the neo gene reconstitution.
TAR cloning of p- and q-arms of the 21HAC4 and their sequencing
Previously, a transformation-associated recombination (TAR) cloning
strategy25 was successfully used to characterize neocentromeres.26 In
this work, we performed TAR cloning and sequencing of the 21HAC
to compare the informative sequences and to conﬁrm that the correct
targeting events were made during the modiﬁcations in DT40 cells.
TAR cloning was used to isolate fragments containing p- and q-arms
of the 21HAC4 propagated in DT40 cells (Figure 3). The p- and q-arm
regions were selectively cloned as circular YACs in yeast using TAR
vectors carrying an arm-speciﬁc unique targeting sequence and an
alphoid DNA repeat as a second targeting sequence (see Materials and
methods section). Transformation experiments were carried out with
freshly prepared yeast spheroplasts and a linearized TAR-speciﬁc
vector as described in Materials and methods section. For each vector,
from three to ﬁve positive clones were identiﬁed using a set of
diagnostic primers. The size of the positive YACs for the p-arm region
was B20kb; the size of the positive YACs for the q-arm region was
B80kb. The YAC clones are relatively stable during propagation in
yeast. For further analysis, circular YACs were retroﬁtted into BACs by
homologous recombination in yeast and transformed into Escherichia
coli (E. coli). Most of BACs rescued in E. coli underwent deletions,
suggesting that the inserts are unstable in bacterial cells. However, after
screening the E. coli transformants, we succeeded in ﬁnding BAC
clones with no detectable rearrangements, when transformation and
subsequent growth of E. coli cells was performed at 301C. Lack of
rearrangements in the BAC inserts was conﬁrmed by comparison of
original YAC isolates, retroﬁtted YAC/BACs and BACs (data not
shown). The #26-2 (q-arm), and #32-2, #37-2 and #40-2 (p-arm)
BACs were chosen for sequencing analysis, and homology search of
the determined sequence of each BAC clone was carried out against
current public databases. The #26-2 is isolate for q-arm, whose size
was about 81kb, and the #32-2, #37-2 and #40-2 were duplicate
isolates for the p-arm, whose size was about 13kb. The sequences are
available from DDBJ/GenBank/EMBL under accession number
AB553833–AB553834. Thus, the sequence data of TAR isolates show
that chromosome truncation during construction of the HAC was
driven exclusively by homologous recombination, and that the
21HAC1 (as well as its derivatives) does not contain any endogenous
gene, and that correct targeting event occurred in loxP site, p-arm and
q-arm. However, as the complete sequence of B100kb pericentro-
meric regions remained in the 21HAC (Figure 3), unknown and
unreported genes or pseudogenes may exist on the 21HAC.
Pulsed-ﬁeld gel electrophoresis and Southern blotting in 21HACs
To investigate the structural integrity of the 21HACs during the
modiﬁcations in DT40 cells, Southern blot analyses were performed
with genomic DNA isolated from DT40 containing the 21HACs,
digested with BamHI. The restriction fragments were size-separated
by pulsed-ﬁeld gel electrophoresis, Southern blotted and hybridized
with a probe to a-satellite derived from human chromosome 21.27
The restriction fragments from the 21HAC1, 21HAC2 and 21HAC4
were consistent with those from the parental hChr.21 (Supplementary
Figure S5). The total size of the 21HACs was estimated to be about
5Mb from the pulsed-ﬁeld gel electrophoresis, Southern blotting and
sequence analyses. These data suggest that the gross structure of the
21HACs was stably maintained during the modiﬁcations in DT40
cells.
Stability of 21HAC2 in vitro
As the 21HAC2 contains EGFP gene for monitoring, we used this
HAC for the following experiments. To investigate the stability of a
HAC in human cells, the 21HAC2 was transferred to human immor-
talized mesenchymal stem cell (hiMSC) line, which was generated and
characterized previously,18 by MMCT. Ten GFP-positive clones were
selected and examined in the following experiments (Figure 5a). PCR
analyses showed that 4 out of the 10 drug-resistant clones were
positive for the markers on the 21HAC2 (data not shown). FISH
analyses showed that the 21HAC2 was present as an individual
chromosome in the hiMSCs (Figure 5b). After the hiMSC
(21HAC2) cells were cultured for about 3 months without selection,
the stability of the 21HAC2 and GFP expression on the 21HAC2 were
tested. FISH analyses revealed that the 21HAC2 was independently
and stably maintained in hiMSCs (Figure 5c), and most of the hiMSC
(21HAC2) cells were GFP-positive (data not shown). These data
suggest that the 21HAC2 can be maintained stably and the EGFP
gene on the 21HAC2 can be expressed stably even after long-term
culture in vitro.
Stability of 21HAC2 in vivo
Next, to demonstrate that this HAC can be used for the generation
of trans-chromosomic mice for the functional analysis of a desired gene
or genes in mice, the 21HAC2 was introduced into the mouse ES cell
lines, TT2F and E14, by MMCT. Ten TT2F lines and seven E14 lines
were GFP-positive clones and so were examined in detail (Figure 5d).
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Gene TherapyPCR analyses using primers for the detection of the 21HAC2 showed
that 9 of the 10 TT2F clones and 6 of the 7 E14 clones contained the
21HAC2 (data not shown). FISH analyses showed that the 21HAC2
was present as an individual chromosome in these mouse ES cells
(Supplementary Figure S6a). In order to determine the developmental
potential of these cells, as well as the expression of the transferred
EGFP in various tissues, chimeric mice were produced from TT2F
(21HAC2) and E14 (21HAC2). Chimeras with various forms of coat-
color chimerism were successfully obtained and GFP-positive chimeric
mice were analyzed. The ﬁve chimeric mice with high coat-color
chimerism were mated, and the 21HAC2 was transmitted through the
germline in three out of the ﬁve chimeric mice. The GFP-positive
trans-chromosomic F1 mice were used for the following analyses. The
EGFP gene driven by the CMVearly enhancer/chicken b actin (CAG)
promoter on the 21HAC2 was expressed in all tissues examined
(Figure 5e), suggesting that the 21HAC2 was stably maintained in
vivo. FISH analyses showed that the 21HAC2 was present as an
individual chromosome in trans-chromosomic tail-ﬁbroblasts
(Figure 5f), and that the 21HAC2 was detected in at least 80% of
kidney, lung, liver and brain cells (data not shown), similar to the
previous reports.15,19 These data suggest that the 21HAC2 does not
interfere with normal development and is stably maintained in mice.
Growth suppression of cells with a HAC in vitro and in vivo
To construct a HAC for safe gene therapy, a suicide gene, HSV-TK,
was inserted into the 21HAC series developed in this study. To assess
whether the HSV-TKon the HAC is functional in vitro and in vivo,t h e
21HAC2 was transferred to the human ﬁbrosarcoma cell line, HT1080,
by MMCT. The HT1080 (21HAC2) cells were characterized by
GFP-ﬂuorescence, PCR and FISH analyses as described above
(Figures 6a and b), and treated with ganciclovir (GCV) in vitro and
in vivo. When the total cell numbers were examined, the in vitro
growth rate of HT1080 (21HAC2) cells was comparable to that of the
parental HT1080 cells without selection (Figure 6c). On the other
hand, the growth rate of HT1080 (21HAC2) cells was remarkably
suppressed by GCV when compared with the growth of the parent cell
line, that is, 105 vs 107 on sixth day (Figure 6d). Thus, the cells
containing the HAC are sensitive to the treatment with GCV.
Next, to determine the effect of GCV in vivo, HT1080 (21HAC2)
and parental HT1080 cells were subcutaneously injected into nude
mice, then GCV was injected to the mice. The tumor weights from
mice harboring HT1080 (21HAC2) cells were signiﬁcantly lower than
those from the parental HT1080 for the concentration of GCV,
compared with the controls (phosphate-buffered saline treatment)
(Po0.01 vs P¼0.923) (Figures 6e and f). These data suggest that
HSV-TK on 21HAC2 is biologically functional in vivo and in vitro.
Puriﬁcation of ES cells without HAC in vitro
To eliminate the HAC from mouse ES cells, E14 cells carrying
the 21HAC2 were selected on GCV-containing medium. In all, 65
out of the 70 drug-resistant clones were GFP-negative. Six of these
GFP-negative clones were analyzed by FISH. The 21HAC2 was not
Figure 5 Stability of 21HAC2 in vitro and in vivo.( a) Morphology of hiMSC (21HAC2) cells. Phase-contrast (top panel) and ﬂuorescence (bottom panel)
micrographs are shown. (b) FISH analyses for hiMSC (21HAC2) cells. An arrow indicates the 21HAC2 and the inset shows an enlarged image of the
21HAC2. Digoxigenin-labeled p11-4, derived from hChr.21 (red) was used to detect the HAC. (c) Mitotic stability of 21HAC2 in hiMSC (21HAC2) cells as a
function of population doubling (PDL). (d) Morphology of E14 (21HAC2) cells. Phase-contrast (top panel) and ﬂuorescence (bottom panel) micrographs are
shown. (e) GFP expression in various tissues of trans-chromosomic (Tc) mouse containing 21HAC2. Bright (left panel) and ﬂuorescence (right panel)
micrographs are shown. (f) FISH analyses for Tc tail-ﬁbroblasts containing the 21HAC2. Digoxigenin-labeled human COT-1 DNA (red) was used to detect the
HAC. An arrow indicates the 21HAC2 and the inset shows an enlarged image of the 21HAC2.
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Gene Therapydetected in any of them, and the karyotype of all these clones was
normal, showing that GCV does not induce chromosomal abnorm-
alities (Supplementary Figure S6b and c).
DISCUSSION
In this work, a novel HAC with a predeﬁned sequence and its
derivatives are described (21HAC1, 21HAC2, 21HAC3 and
21HAC4). As all the 21HAC-derivatives contain the HSV-TK,
they can be used for negative selection in vitro and in vivo.A st h e
21HAC1 does not contain ﬂuorescent gene, the tissue-speciﬁc
promoter-driven ﬂuorescent gene can be inserted to the 21HAC1
for tissue-speciﬁc monitoring. As ﬂuorescent marker gene was
inserted into the 21HAC2 and 21HAC3, cells containing the 21HAC
can be easily monitored after MMCT. As the 21HAC4 contains the
3¢neo-loxP, the RPCI-6 PAC library containing 5¢neo-loxP site can
be transferred into the 21HAC4. Thus, each HAC derivative may be
used for different purposes, including gene cloning/expression
experiments, cell reprogramming and analysis of mitotic segregation
of HAC.
Previously, human immunoglobulin genes (1.5–2Mb) were cloned
into the SC20-HAC, and the human DMD gene (2.4Mb) was cloned
into the 21HAC2 developed in this study, by a combination of Cre-
loxP-mediated chromosome translocation and telomere-directed
truncation in homologous recombination-proﬁcient chicken DT40
cells.13,28 Inserts with a desired gene from the PAC library, RPCI-6, can
be directly cloned into 21DqHAC/21DpqHAC and 21HAC4 without
modiﬁcation of a PAC clone.19 However, only one chromosome
region (or gene) can be cloned into a HAC using the Cre-loxP system.
In this study, two different vectors containing a desired gene were
inserted sequentially into the 21HAC1 by homologous recombination
in DT40 cells. Theoretically, two or more vectors containing a desired
gene can be inserted sequentially into the HAC. Therefore, any
combination of genes, including a full-length genomic DNA, can in
theory be cloned into the HAC derivatives by a combination of these
cloning systems and transferred into a desired cell type using the HAC.
The HAC with a gene of interest can be also transferred to mouse ES
cells, and the chimeric mice or their offspring will be useful either for
functional analyses in vivo or as a disease model.29
During the investigation of the HAC integrity by Southern blotting
with a human chromosome 21-derived alphoid satellite probe, we
found no rearrangement of the restriction fragments of the HAC
centromere in DT40 clones. For the future application of the HAC to
the gene therapy protocol, any rearrangements that may lead to safety
concerns are not desirable even if they are inert. Although several HAC
vectors have proven to be very useful tools,6 previously developed
HAC vectors were structurally undeﬁned, making them unsuitable for
gene and cell therapies in human. In this study, using a TAR cloning
strategy and following sequencing of p- and q-arm regions of the
HAC, we proved that our novel HAC consists of exclusively repetitive
elements representing a functional centromere and does not contain
any endogenous genes. Thus, this HAC has multiple applications for
human therapeutic goals. However, it is important to examine that the
HAC does not induce the malignant transformation. If cells contain-
ing this HAC are transformed to tumor cells, most of the tumor cells,
if not all, can be eliminated by GCV injection in vivo.
Recently, we succeeded in complete genetic correction of induced
pluripotent stem cells from patients with Duchenne muscular
dystrophy using the 21HAC2 containing the entire sequence for
Figure 6 Effect of GCV on HT1080 (21HAC2) with HSV-TK in vitro and in vivo.( a) Morphology of HT1080 (21HAC2) cells. Phase-contrast (top panel) and
ﬂuorescence (bottom panel) micrographs are shown. (b) FISH analyses for HT1080 (21HAC2) cells. An arrow indicates the 21HAC2 and the inset shows an
enlarged image of the 21HAC2. Digoxigenin-labeled p11-4, derived from hChr.21 (red), was used to detect the HAC. (c and d) Growth curve of HT1080 and
HT1080 (21HAC2) cells with d or without c GCV selection in vitro.( e) Tumors derived from HT1080 and HT1080 (21HAC2) cells with (left) or without
(right) GCV treatment. (f) Tumor weight in HT1080- and HT1080 (21HAC2)-derived tissues with phosphate-buffered saline (PBS) or GCV treatment.
A statistical analysis was performed using a two-tailed Student’s t-test.
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Gene Therapyhuman dystrophin.30 Furthermore, we also showed a possibility for
the treatment of glioma using hiMSC containing the 21HAC2 with
HSV-TK.31 However, detail information of construction of the
21HACs had not been reported previously. Thus, the data in this
study are crucial information for the future gene delivery. As mouse
ES cells that have lost the HAC could be selected by GCV, the HAC,
containing deﬁned factors, such as OCT4, SOX2, KLF4, cMYC and
LIN28, may be useful for generating induced pluripotent stem cells
avoiding the problem of insertional mutagenesis.32,33 As the HAC
could be transmitted through the germline and stably maintained
in vivo, it will be useful to generate model animals containing a
megabase-sized gene, such as a HLA cluster (3Mb), CYP3A cluster
(B1Mb) or UGT2 cluster (1.5Mb). Thus, the HACs developed in this
study will be useful not only for gene and cell therapies, but also
for the generation of humanized model animals. Thus, the HACs may
be designated as ‘multipotent vectors’.
MATERIALS AND METHODS
Plasmid construction
The region a to f in Figure 3 shows homologous region on the hChr.21 for the
following targeting vectors. Targeting vectors were constructed as follows. For
5¢HPRT-loxP-Hyg-TK: two 3.4- and 2.8-kb fragments for the homologous
arms, corresponding to AP001657, were ampliﬁed by PCR using primers
#21CEN o141L/#21CENo141R (3.4kb, region d), 5¢-ACCTGGAATTTCC
TACCATCCCCCATAA-3¢ and 5¢-ATCTCTCCAGAGGGACAGCATCATACCC-3¢;
#21CENo241L/#21CENo241R (2.8kb, region e), 5¢- CCTGCAAGTTAT
GACCACTGGGGATTTT-3¢ and 5¢-CTGCAGTGAGCCGAGATCATACCACT
GT-3¢. The PCR products were digested with either EcoRI/BamHI or XhoII
and sub-cloned into EcoRI/BamHI or BglII of pKO Scrambler V901 backbone
vector (Lexicon Genetics, Woodlands, TX, USA), which contained the follow-
ing three selection/insertion cassettes between the AscIa n dKpnI sites: a 2-kb
fragment (MC1-TK) from pKO SelectTK V830 (Lexicon Genetics) contain-
ing the HSV-TK, a 1.4kb ClaI/AscI( 5 ¢HPRT-loxP) fragment from pKO
SelectHPRT V820 (Lexicon Genetics) containing part of the human HPRT
gene with the loxP site inserted at the XbaI site of intron B, and a 1.8kb ClaI/
KpnI fragment (PGK-Hyg) from PGKhygrodetlaLT20 encoding the hygromycin
gene. For pBS-TEL/Dp Puro: a PCR product from AL163201 was ampliﬁed by
PCR with the following primers #21p-BsrGI-BamHI/21p-loxP 3Rb (5.1kb,
region a), 5¢-ACGGATCCTGTACAATACACAGTTGACTGTCTCAGTGTG-3¢
and 5¢-ACGGATCCAAGCCCACATATTATTATGCTGTGCTTC-3¢,d i g e s t e d
with BamHI (5.1kb) and sub-cloned into the BamHI sites of pBS-TEL/Puro
vector.13 For pBS-TEL/Dq HisD: a PCR product from AP001657 was ampliﬁed
by PCR with the following primers q1L/q1R (7kb), 5¢-GGAGCAACAGGACCT
CTCATTCCTTGTT-3¢ and 5¢-CCAATGTCAGGCACTCCTGCTCTAAATG-3¢,
digested with BamHI (7kb, region f) and sub-cloned into the BamHI sites of
pBS-TEL/HisD vector.13 For I-EGFP-I-Bsd: two 3.8- and 2.6-kb fragments for
homologous arms corresponding to AP001657 were ampliﬁed by PCR using
primers #21cenG1L/#21cenG1R (3.8kb, region b1), 5¢-GTGAAGGCATTGCCA
GTGTTTTCTTCTG-3¢ and 5¢-TTTGCCGTAGTCAGTGGGTGAATCATCT-3¢;
#21cenG3L/#21cenG 3R (2.8kb, region c), 5¢-GTTTGAGAGGACATGCAACAC
CCTGAAT-3¢ and 5¢-TTTAGATGCAGGGGCATACTGTGAGCAT-3¢,d i g e s t e d
with either ApaIo rXbaI, and sub-cloned into the equivalent sites of pCMV/
Bsd (Invitrogen). SalI/HindIII fragments of CAG–EGFP from pCX-EGFP
(a gift from Dr M Okabe) were cloned into pJC5-4 (a gift from
Dr G Felsenfeld) including HS4 insulators, then the CAG–EGFP fragments
ﬂanked with the HS4 insulator were cloned into the NotI/XhoI sites of pCMV/
Bsd with two homologous arms. For DsRed-neo: two 3.0- and 3.0-kb fragments
for homologous arms corresponding to AP001657 were ampliﬁed by PCR
using primers #21cenF (PciI ApaLI AscI)/#21cenR(NcoI) (3.0kb, region b2),
5¢-CCCGTGCACGGCGCGCCACTAGCCAGTTTTCCCAGCAC-3¢ and 5¢-CC
CCATGGAAAATATTTTAACAAGAGTTATTGTTTTGC-3¢;# 2 1 c e n F( NcoI-1)/
#21cenR(AscI) (3.0kb, region b3), 5¢-CCCATGGCATATTGTAAATAAGACA
CCCTCCGT-3¢ and 5¢-CCCGGCGCGCCGAGTATCCATGAAGAAATGCACA-
3¢, digested with either PciIo rPciI/AscI and sub-cloned into the equivalent
sites of pDsRed2-Express-N1 (Takara, Ostu, Japan). For I-EGFP-I-loxP-3¢HPRT:
a2 . 3 k bEcoRI/AscI fragment (3¢HPRT-loxP) from pKO SelectHPRT V820
(Lexicon Genetics) containing part of the human HPRT gene with a loxP site
inserted at the XbaI site of intron B, was cloned into the EcoRI/AscIs i t e so f
V901 (V901-3¢HPRT-loxP). Next, the CAG–EGFP constructs ﬂanked with the
HS4 insulator were cloned into V901-3¢HPRT-loxP. For 3¢neo-loxP-Bsd-TK:
BamHI fragment from pSF1 with CMV-Bsd14 was cloned into the BamHI site
of V901 (V901-3¢neo-loxP-Bsd). The AscI/SalI fragments from V901-3¢neo-
loxP-Bsd were cloned into the equivalent sites of V901, inserting the three
fragments #21CEN o141L/#21CEN o141R (3.4kb), MC1-TK (2kb) and
#21CENo241L/#21CENo241R (2.8kb).
Cell culture
Chicken DT40 cells containing hChr.21 were generated previously34 and
maintained at 401C in RPMI 1640 medium supplemented with 10% fetal
bovine serum, 1% chicken serum, 50mM 2-mercaptoethanol and 1.5mgml–1
G418. CHO-K1 or hprt-deﬁcient CHO (CHO (hprt / )) cells used as fusion
recipients for chromosome transfer were maintained at 371Ci nH a m ’ sF - 1 2
nutrient mixture (Invitrogen, Carlsbad, CA, USA) supplemented with 10%
bovine calf serum. Mouse embryonic ﬁbroblasts were isolated from 13.5 days
post coitum embryos. The tail-ﬁbroblasts, mouse embryonic ﬁbroblasts, hiMSC
and human ﬁbrosarcoma (HT1080) cells were grown in Dulbecco’s modiﬁed
Eagle’s medium (Sigma, St Louis, MO, USA) plus 10% fetal bovine serum. The
parental mouse ES cell lines, TT2F and E14, and the microcell hybrid clones,
were maintained on mitomycin C (Sigma)-treated Jcl:ICR (CLEA Japan, Tokyo,
Japan) mouse embryonic ﬁbroblasts as feeder layers in Dulbecco’s modiﬁed
Eagle’s medium with 18% fetal bovine serum (Thermo Scientiﬁc Hyclone,
Yokohama, Japan), 1mM sodium pyruvate (Invitrogen), 0.1mM non-essential
amino acids (Invitrogen), 0.1mM 2-mercaptoethanol (Sigma), 2mML -glutamine
(Invitrogen) and 1000Uml–1 leukemia inhibitory factor (LIF) (Funakoshi,
Tokyo, Japan).
Modiﬁcation of hChr.21 and HAC in DT40 cells
Homologous recombination-proﬁcient chicken DT40 cells (1 107)w e r e
collected in 0.5ml RPMI with 25mg of linearized targeting vector and
electroporated at 550V and 25mF using a Gene Pulser apparatus (Bio-Rad,
Tokyo, Japan). Drug-resistant DT40 clones were then selected in 1.5mgml–1
G418, 1.5mgml–1 hygromycin, 0.3mgml –1 puromycin, 15mgml –1 blasticidin S
or 0.5mgml–1 L-histidinol. Homologous recombination in DT40 hybrid clones
was identiﬁed by PCR as follows. The modiﬁed chromosomes were transferred
to CHO cells via MMCT.
MMCT
MMCT was performed as described previously.23 DT40 containing the HAC
were transferred to CHO cells by MMCT, then CHO cells containing the HAC
were used as donor microcell hybrids. Brieﬂy, mouse ES and hiMSC and
HT1080 cells were fused with microcells prepared from donor hybrid CHO
(21HAC2) cells, and selected with blasticidin S (3–8mgml –1). As a ﬂuorescent
marker gene, such as EGFP, was inserted into the 21HAC2 and 21HAC3, we can
easily monitor which cells contain the 21HAC after MMCT. The transferred
HAC in each line was characterized by PCR, reverse transcription-PCR and
FISH analyses.
FISH analyses
FISH analyses were performed using either ﬁxed metaphase or interphase
spreads of each cell hybrid using digoxigenin-labeled (Roche, Basel, Switzer-
land) human COT-1 DNA (Invitrogen), digoxigenin-labeled p11-4 (hChr.21-
derived a-satellite clone)27 and biotin-labeled DNA (RP6-127C8, PGK-Hygro,
PGK-Puro, b-actin-HisD, CAG–EGFP and CMV-DsRed), essentially
as described previously.23 Chromosomal DNA was counterstained with
4,6-diamidino-2-phenylindole (Sigma). Images were captured using the
NIS-Elements system (Nikon, Tokyo, Japan) or the Argus system (Hamamatsu
Photonics, Hamamatsu, Japan). The 20 metaphases and 100 interphases were
counted for the chromosomal analyses.
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Genomic DNA was extracted from cell lines using a genomic extraction kit
(Gentra System, Minneapolis, MN, USA), and PCR was performed using
standard methods as described previously.19 The primer pairs for detecting the
targeting were described in Supplementary Table S2. DT40, CHO (hprt / ),
CHO-K1, hiMSC, HT1080, E14 and TT2F cells were used as negative controls.
Southern blot analyses
DNA samples were digested with SphI, and the digested samples were separated
on 0.8% agarose gel electrophoresis and transferred to a Hybond N+ mem-
brane (Amersham, Sunnyvale, CA, USA) in an alkaline solution. The mem-
brane was hybridized overnight at 651C with 32P-labeled probes and washed
three times at 651C in 0.1% sodium cloride- sodium citrate (SSC) for 30min,
0.1% sodium dodecyl sulfate for 30min. Radioactivity was visualized by the
imaging ﬁlm (KODAK, Tokyo, Japan). The primer pairs for probes to detect the
targeting of 5¢HPRT-loxP-Hyg-TK at the AP001657 locus were: 21A5-1L/21A5-
1R (649bp, 5¢ probe), 5¢-CAGGCAACTGTAACACAGTGGTAGGTA-3¢ and
5¢-AACAGTAGAGCAATTTCAGGCAGGTC-3¢; 21qA3-3L/21qA3-3R (626 bp,
3¢ probe), 5¢-CGCAGCTTTTAGCTGAACTAAGGAGA-3¢ and 5¢-GTGACA
CAGGGATACTCTGTCCAAAA-3¢.
TAR cloning and sequence analyses
The TAR cloning vectors, pVC-parm/Sat+ and pVC-qarm/Sat , containing
one unique targeting sequence and an alphoid DNA repeat as the second
targeting sequence, were constructed as follows. To construct pVC-parm/Sat+
vector, an 85-bp alphoid DNA sequence35,36 was inserted into BamHI and XbaI
polylinker sites of pVC604 (CEN6-HIS3).37 A unique hook, corresponding
to the open reading frame of Puro from the plasmid pPGKPuro (AF090453),
was also inserted into the polylinker as a 546bp ApaI–BamHI fragment. To
construct the pVC-qarm/Sat  vector, an 85-bp alphoid DNA sequence was
inserted into the ApaIa n dBamHI polylinker sites of pVC604. As a unique
hook for pVC-qarm/Sat  vector, a 186-bp fragment of pBluescript was chosen
(the pBluescript sequence was introduced into the 21HAC during truncation of
the q-arm.). A unique hook was inserted into the BamHI and XbaI polylinker
sites of the TAR vector. All targeting sequences were PCR ampliﬁed using the
pairs of primers presented in Supplementary Table S1. The vectors were cut
with BamHI (this site is located between the alphoid repeat and a unique
sequence) before yeast transformation. The highly transformable Saccharomyces
cerevisiae strain VL6-48 was used for TAR cloning.37 Agarose plugs containing
high molecular weight genomic DNA were prepared from chicken DT40 cells
carrying 21HAC4, and were used for the TAR cloning experiments. Transfor-
mation experiments were carried out with freshly prepared yeast spheroplasts
as previously described.37 In each experiment, approximately 2mgo fg e n o m i c
DNA isolated from DT40 cells carrying 21HAC4, 1mg of the linearized vector
and 8 108 spheroplasts were used. Between 50 and 150 His+ transformants
were then screened by diagnostic primers (Supplementary Table S1) to identify
transformants positive for p- or q-arm-speciﬁc sequences. The diagnostic
primers for centromeric contigs of human chromosome 21 were developed
based on the available human genome sequence.20 Transformants were ﬁrst
combined into pools and examined by diagnostic primers. Then, individual
colonies containing either the p-arm or q-arm sequences were isolated from
each positive pool by a second round of PCR screening. The PCR products
were sequenced to verify that they matched the predicted sequences of hChr.21.
Retroﬁtting of YACs into YACs/BACs, electroporation of YAC/BACs into
E. coli cells, and BAC DNA isolation were carried out as previously described,37
except that electroporation and bacterial culture growth was carried out at
301C to stabilize inserts consisting of pericentromeric repeats. The size of BAC
DNAwas determined after digestion with NotI and further analysis by clamped
homogenous electric ﬁelds (CHEF) gel electrophoresis.
Sequencing of each BAC clone was accomplished using an automated
robotic system and standard procedures. Brieﬂy, BAC DNA was fragmented
for plasmid library construction with an average insert size of 2–4kb using a
HydroShear DNA Shearing Device (Genemachines, San Carlos, CA, USA).
Ampliﬁcation of each plasmid DNA was performed by the rolling circle
ampliﬁcation method (Templiphi DNA Ampliﬁcation Kit, GE Healthcare,
Buckinghamshire, UK). Sequencing of rolling circle ampliﬁcation products
was then carried out using a BigDye terminator v3.1 cycle sequencing kit
(Applied Biosystems, Foster city, CA, USA). Sequencing products cleaned up by
ethanol precipitation were run on automated ABI 3730 capillary sequencers
(Applied Biosystems). The sequence data were assembled using the Phrap/
Consed system.38 Gap closure and re-sequencing of low-quality regions in the
assembled data were done by primer walking on selected clones, the nested
deletion method,39 and construction of short-insert libraries.40
Pulsed-ﬁeld gel electrophoresis and Southern blotting
A high molecular weight DNA for long-range mapping was prepared in agarose
gel plugs as described in Trowell et al.41 The plugs were sliced into segments,
each containing 0.4 106 cells. Agarose-DNA segments were then digested for
18h with BamHI (Takara) (100U per segment). The DNA fragments were size-
separated on a CHEF DR-II apparatus (Bio-Rad Laboratories). The run time
was 24h at 6Vcm–1 with a 60–120s switch time ramp. hChr.21-derived
a-satellite clone p11-427 was labeled with a-32P-dCTP by the random priming
method (Amersham). Hybridization was carried out at 651Ci n0 . 5 M phos-
phate buffer (0.5 M Na2PO4, 7% sodium dodecyl sulfate, 1mM EDTA, pH 7.2).
Following hybridization, the ﬁlters were washed in 40mM phosphate buffer/1%
sodium dodecyl sulfate at 651C. The autoradiographs were obtained by an
imaging system BAS2500 (Fuji Film, Tokyo, Japan).
Reverse transcriptase-PCR analyses
Total RNA was prepared from cultured cells using RNeasy columns, according
to the manufacturer’s instructions (Qiagen, Hilden, Germany), and then was
treated with RNase-free DNase I (Wako, Osaka, Japan). First-strand comple-
mentary DNA synthesis was performed using random hexamers and Super-
Script III reverse transcriptase (Invitrogen). PCR was performed with the
complementary DNA using AmpliTaq Gold (Perkin Elmer, Waltham, MA,
USA). Ampliﬁcations were performed at an annealing temperature of 581Cf o r
30 cycles, and then the ampliﬁed fragments were resolved on a 2% agarose gel,
followed by staining with ethidium bromide. The primer sequences were as
follows: for HPRT (200bp), 5¢-TCCTCCTCCTGAGCAGTCA-3¢ and 5¢-CA
TCTCGAGCAAGACGTTCA-3¢;f o rb-actin (165bp), 5¢-TGTTACCAACTGGG
ACGACA-3¢ and 5¢-GGGGTGTTGAAGGTCTCAAA-3¢.
Generation of chimeric mice
Chimeric mice were produced from the two TT2F (21HAC2) and two E14
(21HAC2) cell lines. Chimera production was performed as described pre-
viously.23 Brieﬂy, the mouse ES cells were injected into eight cell- or blastocyst-
stage embryos derived from ICR mice (CLEA, Tokyo, Japan), and then
transferred into pseudopregnant ICR females. Three chimeric mice showing
100% coat-color chimerism were used for mating. All animal experiments were
approved by the Institutional Animal Care and Use Committee of Tottori
University.
GCV treatment in vitro
HT1080 (21HAC2) cells that express HSV-TK can initially phosphorylate GCV,
leading to an accumulation of its cytotoxic metabolite, GCV triphosphate, and
subsequent incorporation into DNA and apoptosis. To assess the effect of GCV
on the growth of HT1080 (21HAC2) cells in vitro,1  105 HT1080 (21HAC2)
and HT1080 cells were plated with or without 6mM GCV, then the cells were
counted each day for 6 days. Mouse ES cells containing the 21HAC2, E14
(21HAC2) cells, were treated with 6mM GCV, then after 7 days, GFP-negative
clones were analyzed.
Tumor formation and GCV treatment in vivo
To produce tumors, 2 106 HT1080 (21HAC2) and HT1080 cells were
subcutaneously injected into CD-1 (ICR)-nu mice (Charles River, Yokohama,
Japan). After 10 days, the nude mice (n¼6) were treated with an intraperitoneal
injection of GCV (30mgkg–1) or phosphate-buffered saline every day. After 4
weeks, the mice were dissected and the tumors weighed.
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